Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

NCT05565417 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Triple Negative Breast Cancer
Cutaneous Squamous Cell Carcinoma
Hormone Receptor Positive Breast Carcinoma
Small Bowel Cancer
Esophageal Cancer
Colorectal Cancer
Diffuse Large B Cell Lymphoma
Hodgkin Lymphoma
Burkitt Lymphoma
Follicular Lymphoma

Interventions

DRUG: IMT-009
COMBINATION_PRODUCT: Fruquintinib

Sponsor

Immunitas Therapeutics